Alice P. Chen

Research interests

Publications

• Atezolizumab for Advanced Alveolar Soft Part Sarcoma

  New England Journal of Medicine · 2023 · 10.1056/nejmoa2303383

• The NCI-MATCH trial: lessons for precision oncology

  Nature Medicine · 2023 · 10.1038/s41591-023-02379-4

• Dabrafenib and Trametinib in Patients With Tumors With BRAF V600E Mutations: Results of the NCI-MATCH Trial Subprotocol H

  Journal of Clinical Oncology · 2020 · https://doi.org/10.1200/jco.20.00762

• Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W

  Journal of Clinical Oncology · 2020 · https://doi.org/10.1200/jco.19.02630

• The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design

  JNCI Journal of the National Cancer Institute · 2020 · https://doi.org/10.1093/jnci/djz245

• Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation

  Journal of Clinical Oncology · 2020 · 10.1200/jco.19.02931

• Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)

  Journal of Clinical Oncology · 2020 · https://doi.org/10.1200/jco.19.03010

• Nivolumab Is Effective in Mismatch Repair–Deficient Noncolorectal Cancers: Results From Arm Z1D—A Subprotocol of the NCI-MATCH (EAY131) Study

  Journal of Clinical Oncology · 2019 · 10.1200/jco.19.00818

• Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2018 · 10.1200/jco.2018.77.7672

• Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis)

  Journal of Clinical Oncology · 2017 · 10.1200/jco.2016.71.1994

• RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group

  European Journal of Cancer · 2016 · 10.1016/j.ejca.2016.03.082

• RECIST 1.1—Update and clarification: From the RECIST committee

  European Journal of Cancer · 2016 · https://doi.org/10.1016/j.ejca.2016.03.081

• A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study

  Gynecologic Oncology · 2015 · 10.1016/j.ygyno.2015.03.042

• Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors

  Journal of Clinical Oncology · 2015 · 10.1200/jco.2014.60.4009

• Treatment of HCV Infection by Targeting MicroRNA

  New England Journal of Medicine · 2013 · https://doi.org/10.1056/nejmoa1209026

• Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0

  Journal of the American Academy of Dermatology · 2012 · 10.1016/j.jaad.2012.02.010

• A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas

  Clinical Cancer Research · 2012 · 10.1158/1078-0432.ccr-11-2821

• PARP Inhibitor Treatment in Ovarian and Breast Cancer

  Current Problems in Cancer · 2011 · 10.1016/j.currproblcancer.2010.12.002

• Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas

  Cancer Research · 2011 · 10.1158/0008-5472.can-11-1227

• Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study

  Journal of Clinical Oncology · 2011 · 10.1200/jco.2010.34.1636

• PARP inhibitors: its role in treatment of cancer

  癌症：英文版 · 2011 · 10.5732/cjc.011.10111

• Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2008.19.7681

• Overexpression of Phytochelatin Synthase in Arabidopsis Leads to Enhanced Arsenic Tolerance and Cadmium Hypersensitivity

  Plant and Cell Physiology · 2004 · 10.1093/pcp/pch202

• Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV‐PSA) in patients with metastatic androgen‐independent prostate cancer

  The Prostate · 2002 · 10.1002/pros.10130

• Aerobic capacity in adults with various congenital heart diseases

  The American Journal of Cardiology · 2001 · 10.1016/s0002-9149(00)01364-3

Current projects

No projects listed.